Literature DB >> 21418335

Surgical wound complications after heart transplantation.

Andreas Zuckermann1, Markus J Barten.   

Abstract

Surgical wound complications are more frequent in patients undergoing heart transplantation than in other heart surgery patients. This is probably attributed to the presence of additional risk factors in these patients, such as immunosuppression, mechanical support through assist devices and generally poor health. Analyses of wound infections in heart transplantation are based on smaller patient population than those for general heart surgery, and the reported incidences vary largely. The identification of specific risk factors in heart transplant recipients to date is mainly based on retrospective case-control studies in small patient cohorts, the results are controversial, and the comparability of data is limited because of the lack of application of consistent definitions. The impact of immunosuppression and especially immunosuppression with mammalian target of rapamycin (mTOR) inhibitors on the development of surgical wound complications has been widely discussed following reports of increased occurrence with sirolimus. However, nonheart-transplant specific risk factors should also be considered to develop risk profiles and treatment algorithms for individual patients. Data on surgical wound complications in general heart surgery patients and in heart transplant recipients are compared, the impact of modern immunosuppression reviewed, and areas for further investigation discussed.
© 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21418335     DOI: 10.1111/j.1432-2277.2011.01247.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

1.  Indications, Complications, and Outcomes of Cardiac Surgery After Heart Transplantation: Results From the Cash Study.

Authors:  Johannes Gökler; Arezu Z Aliabadi-Zuckermann; Alexandra Kaider; Amrut V Ambardekar; Herwig Antretter; Panagiotis Artemiou; Alejandro M Bertolotti; Udo Boeken; Vicens Brossa; Hannah Copeland; Maria Generosa Crespo-Leiro; Andrea Eixeré-Esteve; Eric Epailly; Mina Farag; Michal Hulman; Kiran K Khush; Marco Masetti; Jignesh Patel; Heather J Ross; Igor Rudež; Scott Silvestry; Sofia Martin Suarez; Amanda Vest; Andreas O Zuckermann
Journal:  Front Cardiovasc Med       Date:  2022-06-09

2.  Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures.

Authors:  Ann Heble; Melanie D Everitt; Jane Gralla; Shelley D Miyamoto; Michael Lahart; Jennifer Eshelman
Journal:  Pediatr Transplant       Date:  2017-12-06

Review 3.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

Review 4.  Everolimus in heart transplantation: an update.

Authors:  Stephan W Hirt; Christoph Bara; Markus J Barten; Tobias Deuse; Andreas O Doesch; Ingo Kaczmarek; Uwe Schulz; Jörg Stypmann; Assad Haneya; Hans B Lehmkuhl
Journal:  J Transplant       Date:  2013-12-05

Review 5.  Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression.

Authors:  Andreas Zuckermann; Uwe Schulz; Tobias Deuse; Arjang Ruhpawar; Jan D Schmitto; Andres Beiras-Fernandez; Stephan Hirt; Martin Schweiger; Laurenz Kopp-Fernandes; Markus J Barten
Journal:  Transpl Int       Date:  2014-11-11       Impact factor: 3.782

6.  Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients: Results of the Prospective Randomized Study EVERHEART.

Authors:  Luciano Potena; Carlo Pellegrini; Francesco Grigioni; Cristiano Amarelli; Ugolino Livi; Massimo Maccherini; Gabriella Masciocco; Giuseppe Faggian; Paola Lilla Della Monica; Gino Gerosa; Nicola Marraudino; Marco Corda; Massimo Boffini
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

7.  Cardiac Surgery After Heart Transplantation: Elective Operation or Last Exit Strategy?

Authors:  Johannes Goekler; Andreas Zuckermann; Emilio Osorio; Faris F Brkic; Keziban Uyanik-Uenal; Guenther Laufer; Arezu Aliabadi-Zuckermann
Journal:  Transplant Direct       Date:  2017-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.